CARGO THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 20th, 2023 • CARGO Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of February 9, 2023, by and among CARGO Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
September 22, 2023 OFFER LETTER Ginna Laport Dear Ginna:Confidentiality and Proprietary Rights Agreement • October 20th, 2023 • CARGO Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
On behalf of CARGO Therapeutics, Inc, a Delaware corporation (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter (the “Agreement’’) is to summarize the terms of your employment with the Company, should you accept our Offer:
FORM OF INDEMNIFICATION AND ADVANCEMENT AGREEMENTForm of Indemnification and Advancement Agreement • October 20th, 2023 • CARGO Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification and Advancement Agreement (“Agreement”) is made as of ________ __, 20__ by and between CARGO Therapeutics, Inc., a Delaware corporation (the “Company”), and ______________, [a member of the Board of Directors/an officer/an employee/an agent] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering indemnification and advancement of expenses.
SUBLEASESublease • October 20th, 2023 • CARGO Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Lease, which includes the preceding Summary and the exhibits attached hereto and incorporated herein by this reference (the Lease, the Summary and the exhibits to be known sometimes collectively hereafter as the “Lease”), dated as of the date set forth in Section 1 of the Summary, is made by and between BP3-SF6 1900 ADLP LLC, a Delaware limited liability company (“Landlord”), and BIGHAT BIOSCIENCES, INC., a Delaware corporation (“Tenant”).
FIRST AMENDMENT TO SUBLEASECARGO Therapeutics, Inc. • October 20th, 2023 • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO SUBLEASE (this “Amendment”) is made as of August 17, 2022 by and between BigHat Biosciences, Inc., a Delaware corporation (“Sublessor”) and Syncopation Life Sciences, Inc., a Delaware corporation (“Sublessee”), with reference to the following facts and objectives:
